We speculate that targeting EphA2 combined with targeting PD-L1 can produce better efficacy than a single drug, that is, targeting EphA2 may enhance the sensitivity of cervical cancer to PD-L1-targeted therapy. Here, EPHA2 is linked to cervical cancer.